<?xml version='1.0' encoding='utf-8'?>
<document id="30248178"><sentence text="The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine."><entity charOffset="93-103" id="DDI-PubMed.30248178.s1.e0" text="metoprolol" /><entity charOffset="108-118" id="DDI-PubMed.30248178.s1.e1" text="paroxetine" /><entity charOffset="119-129" id="DDI-PubMed.30248178.s1.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.30248178.s1.e0" e2="DDI-PubMed.30248178.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30248178.s1.e0" e2="DDI-PubMed.30248178.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30248178.s1.e0" e2="DDI-PubMed.30248178.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30248178.s1.e1" e2="DDI-PubMed.30248178.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30248178.s1.e1" e2="DDI-PubMed.30248178.s1.e2" /></sentence><sentence text="Metoprolol (a CYP2D6 substrate) is often co-prescribed with paroxetine/fluoxetine (a CYP2D6 inhibitor) because the clinical relevance of this drug-drug interaction (DDI) is still unclear"><entity charOffset="0-10" id="DDI-PubMed.30248178.s2.e0" text="Metoprolol" /><entity charOffset="60-70" id="DDI-PubMed.30248178.s2.e1" text="paroxetine" /><entity charOffset="71-81" id="DDI-PubMed.30248178.s2.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.30248178.s2.e0" e2="DDI-PubMed.30248178.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30248178.s2.e0" e2="DDI-PubMed.30248178.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30248178.s2.e0" e2="DDI-PubMed.30248178.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30248178.s2.e1" e2="DDI-PubMed.30248178.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30248178.s2.e1" e2="DDI-PubMed.30248178.s2.e2" /></sentence><sentence text=" This review aimed to systematically evaluate the available evidence and quantify the clinical impact of the DDI" /><sentence text="" /><sentence text="Pubmed, Web of Science, Cochrane Library and Embase were searched for studies reporting on the effect of the DDI among adults published until April 2018" /><sentence text=" Data on pharmacokinetics, pharmacodynamics and clinical outcomes from experimental, observational and case report studies were retrieved" /><sentence text=" The protocol of this study was registered in PROSPERO (CRD42018093087)" /><sentence text="" /><sentence text="We found nine eligible articles that consisted of four experimental and two observational studies as well as three case reports" /><sentence text=" Experimental studies reported that paroxetine increased the AUC of metoprolol three to five times, and significantly decreased systolic blood pressure and heart rate of patients"><entity charOffset="36-46" id="DDI-PubMed.30248178.s10.e0" text="paroxetine" /><entity charOffset="68-78" id="DDI-PubMed.30248178.s10.e1" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.30248178.s10.e0" e2="DDI-PubMed.30248178.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30248178.s10.e0" e2="DDI-PubMed.30248178.s10.e1" /></sentence><sentence text=" Case reports concerned bradycardia and atrioventricular block due to the DDI" /><sentence text=" Results from observational studies were conflicting" /><sentence text=" A cohort study indicated that the DDI was significantly associated with the incidence of early discontinuation of metoprolol as an indicator of the emergence of metoprolol-related side effects"><entity charOffset="115-125" id="DDI-PubMed.30248178.s13.e0" text="metoprolol" /><entity charOffset="162-172" id="DDI-PubMed.30248178.s13.e1" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.30248178.s13.e0" e2="DDI-PubMed.30248178.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30248178.s13.e0" e2="DDI-PubMed.30248178.s13.e1" /></sentence><sentence text=" In a case-control study, the DDI was not significantly associated with bradycardia" /><sentence text="" /><sentence text="Despite the contradictory conclusions from the current literature, the majority of studies suggest that the DDI can lead to adverse clinical consequences" /><sentence text=" Since alternative antidepressants and beta-blockers with comparable efficacy are available, such DDIs can be avoided" /><sentence text=" Nonetheless, if prescribing the combination is unavoidable, a dose adjustment or close monitoring of the metoprolol-related side effects is necessary"><entity charOffset="106-116" id="DDI-PubMed.30248178.s18.e0" text="metoprolol" /></sentence><sentence text="" /></document>